GlycoMark
GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes
DIABETES MANAGEMENT Issue 12 - September 2018
Clinical Viewpoint - The Utility and Impact of GlycoMark Testing
Dear GlycoMark Subscriber,

In our September THE MARK newsletter, we are pleased to include an interview with Dr. Sam Fereidouni, the current Medical Director of Aveon Health in Scottsdale, Arizona and former president of the ADA for Arizona.
Sam Fereidouni, MD, MHSA
Medical Director
Aveon Health
Scottsdale, AZ
What impact has the GlycoMark test had on your practice and your patients?
In today’s environment, with population management and accountable care, many clinicians are waking up to the fact that you need to get patients to goal or you’re not getting paid for services.

By including GlycoMark in the management of our patients with diabetes, our practice has been recognized by national, regional and private payors for exceeding national goals, and recently was also recognized by the American Heart Association for patient risk reduction of chronic diseases including congestive heart failure, myocardial infarction and stroke.
Read the Full Interview
Join Us! Upcoming Sponsored Events:
Exhibiting - American Association of Clinical Endocrinologists (AACE) 11th Annual Meeting New Jersey Chapter
October 6, 2018 - Princeton, NJ

Click here to schedule time to meet with the GlycoMark team.
How to Order the GlycoMark Test:
The GlycoMark test is reimbursed by most federal, state and private payers (CPT Code 84378) and available through various national and regional laboratories, and as a test kit for use on most automated chemistry instruments. Click Here for more information!
The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

For full GlycoMark prescribing information please see our package insert.

Subsequent to incorporating the GlycoMark test into clinical practice, the physician became a paid clinical consultant of GlycoMark.

GlycoMark is a registered trademark of GlycoMark, Inc. © 2018 GlycoMark, Inc. All Rights Reserved. M-64-1A
GlycoMark
805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - info@glycomark.com - www.glycomark.com